Literature DB >> 2682768

MR spectroscopy: clinical perspective.

A M Aisen1, T L Chenevert.   

Abstract

Mesh:

Year:  1989        PMID: 2682768     DOI: 10.1148/radiology.173.3.2682768

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


× No keyword cloud information.
  7 in total

Review 1.  Complementarity of magnetic resonance spectroscopy, positron emission tomography and single photon emission tomography for the in vivo investigation of human cardiac metabolism and neurotransmission.

Authors:  A Syrota; P Jehenson
Journal:  Eur J Nucl Med       Date:  1991

2.  Energy status and metabolism in intracranial space occupying lesions: a prospective 31p spectroscopic study.

Authors:  Ravindra Bhimrao Kamble; Jayakumar Peruvumba N; Ravishankar Shivashankar
Journal:  J Clin Diagn Res       Date:  2014-11-20

3.  Advanced MRI: translation from animal to human in brain tumor research.

Authors:  Bradford A Moffat; Craig J Galbán; Alnawaz Rehemtulla
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

4.  Human in-vivo 31P MR spectroscopy of benign and malignant breast tumors.

Authors:  J M Park; J H Park
Journal:  Korean J Radiol       Date:  2001 Apr-Jun       Impact factor: 3.500

5.  In vivo 31P magnetic resonance spectroscopy (MRS) of tender points in patients with primary fibromyalgia syndrome.

Authors:  A C de Blécourt; R F Wolf; M H van Rijswijk; R L Kamman; A A Knipping; E L Mooyaart
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

6.  Phosphorus-31 nuclear magnetic resonance in vivo spectroscopy of human liver during hepatitis A virus infection.

Authors:  Y Yamane; M Umeda; T O'uchi; T Mitsushima; K Nakata; S Nagataki
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

7.  Application of 31P MR spectroscopy to the brain tumors.

Authors:  Dong-Ho Ha; Sunseob Choi; Jong Young Oh; Seong Kuk Yoon; Myong Jin Kang; Ki-Uk Kim
Journal:  Korean J Radiol       Date:  2013-05-02       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.